ALX Oncology reports breast cancer trial data with CD47 biomarker

ALX Oncology reported encouraging Phase 1b/2 data for evorpacept plus zanidatamab in HER2-positive metastatic breast cancer, including a 100% confirmed objective response rate in the 5-patient high-CD47 subgroup and 33% overall ORR across 24 patients. The stock has already reacted sharply, rising nearly 23% over the past week and 7%+ in premarket trading, after gaining 332% over the past year. Results were consistent with prior HER2-positive gastric cancer findings, and management will discuss the data alongside Q1 2026 results on Friday.

Analysis

This is less a broad “ALXO rerating” and more a very specific biomarker-driven signal that the market can underwrite only if the data are reproducible in a larger, less-selected population. The 5/5 response signal in the CD47-high subgroup is the kind of result that can force fast sentiment repricing in a microcap biotech, but the dispersion versus CD47-low patients suggests the commercial value is still conditional on a companion-diagnostic-like enrichment strategy. That makes the second-order winner the biomarker/testing ecosystem and the partner asset, while the main risk is that investors extrapolate a small, deeply pretreated cohort into platform-level efficacy.

From a trading standpoint, the move likely has a shorter half-life than the headline suggests because the stock has already front-ran on a week-long squeeze, and liquidity at this market cap can unwind quickly if the webcast or Q1 call fails to expand on enrollment, durability, or CD47 assay reproducibility. The key catalyst over the next 1-2 weeks is not the abstract response rate; it is whether management can frame a clean path to an enriched registrational cohort and avoid questions around sample size, prior therapy heterogeneity, and whether the effect is additive to zanidatamab rather than truly synergistic. If the market starts discounting “one more promising combo” rather than “pivotal probability upgrade,” a large fraction of the recent gains can retrace.

The contrarian miss is that this does not yet solve ALXO’s financing overhang, even with more cash than debt; a positive data read can actually encourage more spend on expansion trials before definitive partnering leverage is established. In our view, the best risk/reward is not outright chasing spot after the gap, but expressing a view through optionality or by fading the overextended move into the event calendar. For WFC, the read-through is minimal and likely limited to incremental sentiment around coverage calls; for CRNX, there is no direct fundamental linkage and any sympathy move would be purely factor/biotech-beta driven.

Key Decisions for Investors

• Short-term fade: reduce or short ALXO into strength over the next 3-7 trading days; the setup is vulnerable to mean reversion if webcast details do not materially de-risk the biomarker thesis. Risk/reward favors a tight stop above the post-data momentum high.
• If seeking upside exposure, buy ALXO call spreads expiring after the Q1 webcast rather than stock; this captures continuation risk while limiting drawdown if management commentary is incremental rather than transformative.
• Relative-value trade: long a diversified large-cap oncology basket vs short ALXO for 2-6 weeks to isolate event-risk compression and avoid binary trial-volatility. Best if biotech sentiment stays firm but microcap clinical names give back gains.
• Watch for a financing/partnering catalyst over 1-3 months; if the company uses the data to initiate a capital raise, consider selling any residual long into the strength because dilution would cap upside even with encouraging efficacy.
• Do not chase WFC or CRNX on this headline; any move there should be treated as noise unless a separate analyst/clinical catalyst emerges.